Hsieh Yi-Ling, Yu Weili, Xiang Yanqiao, Pan Weitao, Waterman Kenneth C, Shalaev Evgenyi Y, Shamblin Sheri L, Taylor Lynne S
Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, USA; Allergan Inc., Irvine, CA, USA.
Pfizer Inc, Pharmaceutical Development, Groton, CT, USA.
Int J Pharm. 2014 Jan 30;461(1-2):322-30. doi: 10.1016/j.ijpharm.2013.11.054. Epub 2013 Dec 8.
Oxidation of active pharmaceutical ingredients is a common chemical degradation process occurring in solid dosage forms. The aim of this study was to investigate the tendency of various sertraline salts to oxidize in powder blends containing a basic additive. A different extent of conversion of each salt to the free base was observed to occur in the presence of the basic additive, consistent with their respective pHmax values. Sertraline was found to undergo oxidation as the unioinized form, in both solution and powder blends that incorporated an oxidizing agent. In contrast, the ionized form of sertraline remained stable in both cases. Three sertraline salts undergoing a significant extent of conversion from salt to free form in the presence of tribasic sodium phosphate were found to oxidize extensively while sertraline benzoate which had a considerably lower extent of free base formation was more resistant to oxidation. The oxidative degradants were produced through oxidation at the amine functional group of sertraline which is where sertraline is ionized as the salt form. The link between oxidation tendency and the ionization state of sertraline in powder mixtures has thus been demonstrated in this study.
